Stada and Xbrane Add Two To Biosimilar Development Alliance

31 May 2019

• By Aidan Fry

Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.

Sum — Stada and Xbrane have added certolizumab and nivolumab to their existing biosimilar alliance covering ranibizumab • Source: Shutterstock

Stada Arzneimittel and Xbrane Biopharma have expanded their strategic biosimilar development partnership to cover pre-clinical programs for certolizumab pegol and nivolumab, as well as potentially other early-stage candidates.

“Xbrane and Stada will focus on biosimilars to originator products with patent expiration 2025-2030 and have identified two programs in...